Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Authors

Stanley Cohen

Published

August 31, 2006

Share your thoughts on this paper...

Supporters

Support the authors with ResearchCoin

Journal

Arthritis & Rheumatism

Topics

DOI

10.1002/art.22025

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Authors

Stanley Cohen

Published

August 31, 2006

Share your thoughts on this paper...

Supporters

Support the authors with ResearchCoin

Journal

Arthritis & Rheumatism

Topics

DOI

10.1002/art.22025

Paper

Paper

Paper

Paper

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Supporters

Journal

Topics

DOI

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Supporters

Journal

Topics

DOI